Genetic modifiers of EGFR dependence in non-small cell lung cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 52, 2014, Pages 18661-18666

  Sharifnia, Tanaz ^a,b,c   Rusu, Victor ^a,b   Piccioni, Federica ^a   Bagul, Mukta ^a   Imielinski, Marcin ^a,b,c   Cherniack, Andrew D ^a   Pedamallu, Chandra Sekhar ^a,c   Wong, Bang ^a   Wilson, Frederick H ^a,c   Garraway, Levi A ^a,c   Altshuler, David ^a,b,d   Golub, Todd R ^a   Root, David E ^a   Subramanian, Aravind ^a   Meyerson, Matthew ^a,b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; ORF

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; ITK PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOS PROTEIN; MSTR1R PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EMT PROTEIN-TYROSINE KINASE; FGFR1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; RAF PROTEIN; RON PROTEIN; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE LOSS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MODIFIER GENE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MOS; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, TRKA;

EID: 84924325933     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1412228112     Document Type: Article

References (36)

1. Weinstein IB (2002) Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297(5578):63-64.
2. Paez JG, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500.
3. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139.
4. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306-13311.
5. Mok TS, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957.
6. Rosell R, et al.; Spanish Lung Cancer Group (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958-967.
7. Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18(1):73-79.
8. Bivona TG, et al. (2011) FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339):523-526.
9. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043.
10. Takezawa K, et al. (2012) HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2(10):922-933.
11. Cheung HW, et al. (2011) Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 1(7):608-625.
12. Zhang Z, et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44(8):852-860.
13. Bachleitner-Hofmann T, et al. (2008) HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 7(11):3499-3508.
14. Harbinski F, et al. (2012) Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov 2(10):948-959.
15. Wilson TR, et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487(7408):505-509.
16. Stommel JM, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848):287-290.
17. Yang X, et al. (2011) A public genome-scale lentiviral expression library of human ORFs. Nat Methods 8(8):659-661.
18. Johannessen CM, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968-972.
19. Yeo WL, et al. (2010) Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 5(7):1048-1053.
20. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786-792.
21. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169-181.
22. Sos ML, et al. (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119(6):1727-1740.
23. Lu Y, Liang K, Li X, Fan Z (2007) Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer 6:63.
24. Hatzivassiliou G, et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287):431-435.
25. Biscardi JS, et al. (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274(12):8335-8343.
26. Faber AC, et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 106(46):19503-19508.
27. Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6(3):209-214.
28. Stabile LP, et al. (2013) c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res 19(2):380-392.
29. Lu Y, et al. (2007) Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67(17):8240-8247.
30. Wheeler DL, et al. (2009) Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8(8):696-703.
31. Park KS, et al. (2014) CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J Clin Invest 124(7):3003-3015.
32. Kanda R, et al. (2013) Erlotinib resistance in lung cancer cells mediated by integrinbeta1/Src/Akt-driven bypass signaling. Cancer Res 73(20):6243-6253.
33. Ware KE, et al. (2013) A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2:e39.
34. Terai H, et al. (2013) Activation of the FGF2-FGFR1 autocrine pathway: A novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res 11(7):759-767.
35. Ware KE, et al. (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 5(11):e14117.
36. Sequist LV, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26.